I did not know that, but then I only came aboard t
Post# of 148185
Odd that it was such a small study ($10k), hard to know why you'd need a Pfizer-level company to be involved, also hard to know what they (Pfizer) got in return for being involved (or what they are still possibly owed).
Finally, was it GvHD or NASH that was not conducted in a industry standard manner, and that necessitated a redo? If it was GvHD, then hard to know why Pfizer would have wanted the study conducted that way.